chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Getting numbness in right hand real bad; tingling in my left hand and in my feet sometimes; This is a spontaneous report from a contactable consumer (patient). A 72-year-old male patient received bnt162b2 (BNT162B2 reported as Pfizer COVID 19 Vaccine), at vaccination age of 72-year-old via an unspecified route of administration on 13Apr2021 (Batch/Lot number was not reported) as dose number unknown, single for covid-19 immunisation. Medical history included blockage in heart and has got congestive heart problem. Concomitant medications included apixaban (ELIQUIS); isosorbide mononitrate; torasemide (TORSEMIDE); and clopidogrel bisulfate (PLAVIX), all indication, start and stop date were not reported. The patient previously received a flu shot. On an unspecified date in 2021, the patient experienced getting numbness in right hand really bad and tingling in his left hand and in his feet sometimes. The patient reported that he took his last Pfizer shot in 13Apr2021. He was 72-year-old and he have got congestive heart problem (intent history), but anyway. But now (2021), he was getting some numbness in his right hand really bad and some tingling in his left hand and in his feet sometimes. He will go to his cardiologist on Wednesday, he said we are having some problems with Pfizer shot is causing this. He said it has nothing to do with his heart. The patient wants to know if it is true and what he needs to do because he is due to get his booster in two weeks. He added that it just got worst and worst. It was getting worst every month. When asked about treatment, the patient responded with no, he does not know if any of that do with Pfizer could be caused by his flu shot until Wednesday (further clarification unknown). He went to his heat doctor, his cardiologist on the 20th for a checkup for his heart. So, he was telling about the tingling in his feet, his hands, and the numbness. He said there is a problem (incomplete sentence), some people are having allergic reactions to Pfizer. He said did you take Pfizer and the patient said yes. Well, see his problem is he was due to take his booster in two weeks. The last person, they won't give me his booster in two weeks and he needed to speak to somebody with Pfizer because he doesn't want to take this booster since his numinous and his legs will get worse. He added that he was on wheelchair (pending clarification). The patient underwent lab tests and procedures which included investigation with unknown results on an unspecified date. The outcome of the events was unknown.  The lot number for BNT162b2 was not provided and will be requested during follow up.
vaccine apparently triggered metastatic breast or endometrial cancer to appear in the liver;prior to vax, cancer had been totally treated w/surgery & had assurance that was 95% cured;
he has a little loss of smell, some smells he can smell, some he can't/Cannot smell a little bit, sometimes he can or sometimes he cant, loss of some sense of smell; This is a spontaneous report from a contactable consumer (patient's wife)   A 38-year-old male patient received first BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number/expiration date unknown) on an unspecified date in Jan2021 at single dose via an unspecified route of administration for COVID-19 immunization. Relevant medical history and concomitant medications were reported as none. On 25Jan2021 the patient experienced a little loss of smell, some smells he can smell, some he can't, no fever, no nausea, no shaking. The reporter would ask if could be related to the vaccine. At the time of the reporting event outcome was unknown.   Information about lot/batch number has been requested.
Rash raised welts on legs, buttocks, and torso. Tingling and itching in fingertips
Needle bent while receiving the Moderna Covid 19 vaccine; pharmacist bent the needle in his left tight; This spontaneous case was reported by a patient family member or friend and describes the occurrence of NEEDLE ISSUE (Needle bent while receiving the Moderna Covid 19 vaccine) and WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (pharmacist bent the needle in his left tight) in a 3-year-old male patient who received mRNA-1273 (Spikevax) (batch no. A51416B) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Jun-2022, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 22-Jun-2022, the patient experienced NEEDLE ISSUE (Needle bent while receiving the Moderna Covid 19 vaccine) and WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (pharmacist bent the needle in his left tight). At the time of the report, NEEDLE ISSUE (Needle bent while receiving the Moderna Covid 19 vaccine) and WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (pharmacist bent the needle in his left tight) outcome was unknown.            No allergies was not reported by the reporter. Concomitant medication details were not reported by the reporter.  when the patient received vaccine, the pharmacist bent the needle in his left tight. The mother had now doubts and was worried because she was not sure if patient received the correct vaccine and dosage for his age group. The mother asked the pharmacist if she had administered the 30 mg of the vaccine and the Pharmacist said yes, But the mother was not sure if pharmacist was really paying attention. She was panicked because she did not know if the dosage of patient was received correct. The pharmacist said that the patient was able to receive the full dose, even though the needle bent.  Treatment details was not reported by the reporter.
RVP resulted positive for COVID- 19 and rhinovirus; RVP resulted positive for COVID-19 and rhinovirus; This is a spontaneous report received from contactable reporter(s) (Physician).  A 72-year-old female patient received BNT162b2 (BNT162B2), on 27Feb2021 as dose 1, single (Batch/Lot number: unknown) and on 20Mar2021 as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: COVID-19 (hospitalization, medically significant) with onset 21Feb2022, outcome "unknown", described as "RVP resulted positive for COVID- 19 and rhinovirus"; VACCINATION FAILURE (hospitalization, medically significant) with onset 21Feb2022, outcome "unknown", described as "RVP resulted positive for COVID-19 and rhinovirus". The patient was hospitalized for covid-19, vaccination failure (start date: 2022). The patient underwent the following laboratory tests and procedures: Basophil count: (21Feb2022) 0.0, notes: k/mcl; Eosinophil count: (21Feb2022) 0.0, notes: k/mcl; Full blood count: (21Feb2022) 5.0, notes: K/mcL; Haemoglobin: (21Feb2022) 12.0 g/dl; Lymphocyte count: (21Feb2022) 0.2, notes: k/mcl; Monocyte count: (21Feb2022) 1.2, notes: k/mcl; Neutrophil count: (21Feb2022) 3.02, notes: k/mcl; Platelet count: (21Feb2022) 181, notes: k/mcl; Red blood cell count: (21Feb2022) 4.37, notes: M/mcL; Respiratory viral panel: (21Feb2022) positive for COVID- 19 and rhinovirus. Therapeutic measures were taken as a result of covid-19, vaccination failure. On 21Feb2022, RVP (Respiratory Viral Panel) resulted positive for COVID- 19 and rhinovirus. Patient was treated for COVID-19 with remdesivir for 5 days and dexamethasone 6 mg, daily, for 10 days. Patient maintained on 2-3L nasal cannula. On 01Mar2022, dexamethasone was changed to prednisone 40 mg, orally, for 5 days. On 01Mar2022, patient remained stable on room air for 48 hours and was discharged to home.   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Based on limited information in the case , a possible causal association between  all the reported  events covid 19, vaccination failure and the suspect drug BNT162B2 cannot be excluded.
Herpes Zoster outbreak on R flank, zoster confirmed by culture, treated with valtrex 1 g PO TID x 8 days. Zoster became disseminated, involving the face and arms, valtrex was continued for 14 additional days. Symptoms resolved with mild post-heretic neuralgia follow up on 3/4/21. No outbreak of zoster occurred after second dose of vaccine, which was given 3 weeks after first. Follow up with ophthalmology showed no ocular herpetic pathology.
wrong moderna bivalent admistered. patient was outreached. appointment scheduled for 6/3/23
diffuse itching, palms, hands, neck, back, legs at time of reporting > 5 days not very responsive to antihistamines
Drug ineffective; tested positive for COVID; This is a spontaneous report received from contactable reporter(s) (Nurse).  A 71-year-old male patient received BNT162b2 (BNT162B2), on 14Jan2021 as dose 1, single (Batch/Lot number: unknown), on 02Feb2021 as dose 2, single (Batch/Lot number: unknown), on 23Sep2021 as dose 3 (booster), single (Batch/Lot number: unknown) and on 28Apr2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 70 years for covid-19 immunisation. The patient's relevant medical history included: "hypertension" (unspecified if ongoing), notes: other medical history: hypertension, RLS, sleep apnea,, Metabolic syndrome, Obesity,, hyperlipidemia, insomnia; "RLS" (unspecified if ongoing), notes: other medical history: hypertension, RLS, sleep apnea,, Metabolic syndrome, Obesity,, hyperlipidemia, insomnia; "sleep apnea" (unspecified if ongoing), notes: other medical history: hypertension, RLS, sleep apnea,, Metabolic syndrome, Obesity,, hyperlipidemia, insomnia; "Metabolic syndrome" (unspecified if ongoing), notes: other medical history: hypertension, RLS, sleep apnea,, Metabolic syndrome, Obesity,, hyperlipidemia, insomnia; "Obesity" (unspecified if ongoing), notes: other medical history: hypertension, RLS, sleep apnea,, Metabolic syndrome, Obesity,, hyperlipidemia, insomnia; "hyperlipidemia" (unspecified if ongoing), notes: other medical history: hypertension, RLS, sleep apnea,, Metabolic syndrome, Obesity,, hyperlipidemia, insomnia; "insomnia" (unspecified if ongoing), notes: other medical history: hypertension, RLS, sleep apnea,, Metabolic syndrome, Obesity,, hyperlipidemia, insomnia; "known allergies: Yes" (unspecified if ongoing), notes: known allergies: Yes. The patient's concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), outcome "not recovered"; COVID-19 (medically significant), outcome "not recovered", described as "tested positive for COVID". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (04Jun2022) Positive, notes: Patient tested positive for COVID on 04Jun2022; (17Jun2022) Negative, notes: Then on June 17th, patient started having COVID symptoms again; (19Jun2022) Positive, notes: On June 19th, patient tested positive for Covid again. Therapeutic measures were taken as a result of drug ineffective, covid-19.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: The vaccine efficacy varies from one patient to another and can be affected by different factors; however, a contributory role of the suspect vaccine BNT162B2 to the vaccination failure (LOE) cannot be ruled out.
pain and redness at site of injection; redness and pain at injection site; gave injection subcutaneously; This case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix (subcutaneous). On an unknown date, less than a week after receiving Shingrix, the patient experienced injection site erythema, injection site pain and intramuscular formulation administered by other route. On an unknown date, the outcome of the injection site erythema, injection site pain and intramuscular formulation administered by other route were unknown.   It was unknown if the reporter considered the injection site erythema and injection site pain to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient had his first injection of Shingrix last week but pharmacist gave injection subcutaneously near his tricep and not intramuscularly in his deltoid.  The patient experienced redness and pain at injection site. The reporter did not consent to follow-up.
About 48 hours after first vaccine dose I started feeling really itchy. Followed by large patches of hives showing up all over my body. Individual patches last about 10 minutes but the hives are continuous throughout the day. Also possibly related, experienced stabbing chest pain a couple times throughout the week.  Over 5 days after onset of hives, the severity and consistency has not decreased at all.
Febrile seizure 3 days post vaccine; fever 102.0 axillary at time of seizure.
Patient started shaking and saying she felt dizzy.  Mom laid patient's head down on bed and patient started having jerking motions of both arms, possible jerking of bilateral legs. Eyes were open but not focused. Provider came into room about 5-10 seconds after shaking started, asked patient for their name and patient was able to respond and sit up within 5 seconds. Shaking lasted approximately 15-20 seconds total. Patient also peed her pants during this episode. No tongue biting. No post ictal afterwards. Patient alert and oriented immediately afterwards but was crying due to distress of peeing on herself. Blood sugar checked immediately after episode and was in 90s, patient had eaten prior to coming to appointment.
Pain in site of injection, malaise, chills, retro orbital pain for approximately 24h.
I did not have an adverse reaction to the vaccine. I did not have any symptoms prior to 01/07/2022 of getting sick but I tested positive for COVID-19 on 01/07/2022. I have congestion, sore throat, sore throat and I hurt all over. I contacted my doctor and got a prescription for PAXLOVID and a cough syrup.
Hypersensitivity Information has been received from a pharmacist concerning a 21 year old female who in 2004 was vaccinated with a dose of varicella virus vaccine live (Oka/Merck). Subsequently, in 2004, the patient developed a reaction from the gelatin. Unspecified medical attention was sought. Subsequently, the patient recovered. There was no product quality complain involved. Additional information has been requested.
CHEST PAIN; TWO HEART ATTACKS; This spontaneous report received from a patient via the VAERS (Vaccine Adverse Event Reporting System; VAERS ID 1202551] concerned a 54 year old white not Hispanic or Latino male. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included the patient did not had allergies to medications, food, or other products, did not had other illnesses at the time of vaccination, up to one month prior and did not had spleen. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: 1802070, expiry: UNKNOWN) dose was not reported, administered on 10-MAR-2021 12:00 for prophylactic vaccination on right arm. Concomitant medications included lisinopril for drug used for unknown indication. On MAR-2021, the patient experienced two heart attacks, first attack was on day of vaccine and another was the day after the vaccine and was hospitalized (date unspecified). On 16-MAR-2021 04:00, the patient experienced chest pain prior to each heart attack but had never suffered chest pain before. He further reported that he was continuing to suffer from periods of chest pain at rest.  Laboratory data (dates unspecified) included: Cardiac catheterization (NR: not provided) 20 to 30 percentage blockage. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from two heart attacks. This report was serious (Hospitalization Caused / Prolonged, Life Threatening, and Disability Or Permanent Damage).; Sender's Comments: V0. 20210439984-covid-19 vaccine ad26.cov2.s -Two heart attacks, Chest pain- This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).
Body aches, fever, headache, sore throat, coughing, congestion, no taste, loss of appetite.
Information has been received from a pharmacist via company representative referring to a patient of unknown demographics. Patient's relevant medical history, concurrent conditions and drug reactions/allergies were not reported. Reporting pharmacist stated that on an unspecified date (reported as a long time ago), the patient received ZOSTAVAX (strength, dose/frequency, lot # unspecified) that may have been improperly stored. Concomitant medications were not reported. No adverse effect was reported. Additional information is not expected as the reporter did not wish further contact.
I am currently on oxygen. This began in January. 24 hours after having booster, I had fever and lethargy and was unable to function, It dissipated after 2 days. In January I was unable to breath and could not get my pulse ox above 60. I had an awful cough.
This spontaneous report as received from a healthcare professional refers to a patient of unknown age and gender. The patient's medical history and concurrent conditions were not reported. On 25-APR-2015, the patient was vaccinated with an improperly stored ROTATEQ, 1 dose 2 ml orally, (lot number were not reported). The patient's concomitant therapies were not reported. Adverse effects were not reported. Additional information has been requested.
Left testicle inflammation.   Hurt to the touch for 3 days after vaccine.  No trouble with any excretory function, void normal.
Vertigo the morning after the shot. Very slight dizziness the rest of the day. Vertigo was back the next day in the morning just after waking up.
Pt was not given full dose of shingrix some of it spilled out. Therefore advised to be vaccinated again at same time on other arm. Pt felt that we purposfully or mistakenly wanted to give her  the shot again. Same day she also recieved the prevnar. I asked her if she felt comfortable with getting the prevnar still indicating she may be under the weather. Asked her to stick around to monitor her but she left. In our survey she indicated being afraid of getting too much shingrix. I explained to her she didnt get the full dose. She went to her doctors to get checked and reported in a survey that she got a headache and wasnt feeling too well.
Pt is experiencing multiple joint pain for 1 yr. He had his first anthrax vaccine in 2008 - unknown date, but given at a certain location.
loss of taste; This is a spontaneous report from a Pfizer-sponsored Program. A contactable female consumer (patient) reported for herself that she received first dose of bnt162b2 (BNT162B2, Solution for injection, lot number not reported), via an unspecified route of administration on 31Mar2021 as single dose for COVID 19 immunisation. The patient medical history and concomitant medications were not reported. On an unknown date in 2021, patients husband was tested Covid-19 Positive, and she experienced loss of taste. The patients second dose schedule which will be on 11Apr2021. The outcome of the events was reported as unknown.  Information about lot/batch number cannot be obtained.  No follow-up attempts are needed. No further information is expected.
PATIENT HAD SINGLE EPISODE OF VOMITING SHORTLY AFTER RECEIVING THE VACCINE.
Injection site tenderness; Fatigue; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program (159558). The reporter is the patient.  A 45 year-old female patient received bnt162b2 (BNT162B2), administration date 29Mar2021 (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose: 1), for Covid-19 immunization. The following information was reported: VACCINATION SITE PAIN (non-serious), outcome "unknown", described as "Injection site tenderness"; FATIGUE (non-serious), outcome "unknown", described as "Fatigue".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Labelled drug-drug interaction; Itchy; Large swelling on my arm; Sore arm; This case was reported by a consumer via interactive digital media and described the occurrence of swelling arm in a female patient who received DTPa (Reduced antigen) (Tdap Vaccine) for prophylaxis  Co-suspect products included Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent 2019-2020 season) for an unknown indication.   In October 2019, the patient received Tdap Vaccine and Influenza vaccine Quadrivalent 2019-2020 season. In October 2019, less than a week after receiving Tdap Vaccine and Influenza vaccine Quadrivalent 2019-2020 season, the patient experienced swelling arm and pain in arm. On 20th October 2019, the patient experienced pruritus. On an unknown date, the patient experienced labelled drug-drug interaction medication error. On an unknown date, the outcome of the swelling arm, pain in arm and pruritus were not recovered/not resolved and the outcome of the labelled drug-drug interaction medication error was unknown.   It was unknown if the reporter considered the swelling arm, pain in arm and pruritus to be related to Tdap Vaccine and Influenza vaccine Quadrivalent 2019-2020 season.  Additional details were priovided as follows: The age at vaccination was not reported. The patient stated that, a week ago received Flu shot and Tdap shot in the same unknown arm. The patient did not know which vaccine had the patient sore and swollen because they gave in the same arm. On the day of reporting, the patient had itching.
Patient stated she could not breathe and was red and flushed in arms and face within 1 to 2 minutes after administration. I administered one 0.3mg epinephrine injection at 3:00pm.  Patient stated she was feeling better and the redness subsided within a few minutes.  EMS was called and arrived about 18-20 minutes after epipen.  The patient's vitals were within normal limits and patient was feeling better.   EMS consulted patient's mom.  Patient's mom elected to take patient home (about 40 minutes after incident) and observe for any additional reactions.
Site: Itching at Injection Site-Medium, Site: Redness at Injection Site-Medium, Systemic: Allergic: Rash (specify: facial area, extremeties)-Medium, Systemic: Dizziness / Lightheadness-Severe, Systemic: Flushed / Sweating-Mild, Additional Details: Patient had BP taken and it was normal, continued to be dizzy after 30-45 minutes of sitting. He had to sit on the floor. EMS was called and monitored him. Nothing further was reported